Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Engenome S R L holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active. These actions are distributed among a matching number of distinct examiners and 2 distinct art units. This distribution indicates that the company's innovations are being evaluated by multiple technical divisions, requiring a multi-faceted approach to prosecution.
STUBBS, JOHN THOMAS is the busiest examiner for this portfolio. This examiner is currently handling 1 pending office action. This represents a portion of the total pending office actions currently active for the company. Because the workload is split between the examiners, no single individual dominates the current prosecution landscape.
The involvement of 2 distinct art units suggests that the company's research spans different specialized classifications within the Biotechnology & Pharmaceuticals field. With multiple examiners involved, the company must manage separate sets of examiner preferences and interpretations. This requires the company to tailor its legal arguments to different individual perspectives while maintaining consistency across the portfolio. Resolving the issues raised by STUBBS, JOHN THOMAS is a key step.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STUBBS, JOHN THOMAS | 1 | — | — |
| WISE, OLIVIA M. | 1 | 33.9% | +29.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550662 | PREDICTIVE METHOD FOR DETERMINING THE PATHOGENICITY OF COMBINATIONS OF DIGENIC OR OLIGOGENIC VARIANTS | STUBBS, JOHN THOMAS | — |
| 18040604 | METHOD FOR DETERMINING THE PATHOGENICITY/BENIGNITY OF A GENOMIC VARIANT IN CONNECTION WITH A GIVEN DISEASE | WISE, OLIVIA M. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040604 | METHOD FOR DETERMINING THE PATHOGENICITY/BENIGNITY OF A GENOMIC VARIANT IN CONNECTION WITH A GIVEN DISEASE | WISE, OLIVIA M. | — |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18550662 | PREDICTIVE METHOD FOR DETERMINING THE PATHOGENICITY OF COMBINATIONS OF DIGENIC OR OLIGOGENIC VARIANTS | STUBBS, JOHN THOMAS | 1686 | §101§103 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18040604 | METHOD FOR DETERMINING THE PATHOGENICITY/BENIGNITY OF A GENOMIC VARIANT IN CONNECTION WITH A GIVEN DISEASE | WISE, OLIVIA M. | 1685 | §101§103§112 | Non-Final OA | — | Pending | Feb 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEngenome S R L has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
John Thomas Stubbs has the most, with 1 of Engenome S R L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
